Linda Sasset
Senior Scientist RenBio
Seminars
Thursday 16th July 2026
DNA-Encoded Metabolic Transformation by Leveraging In Vivo Protein Production to Redefine Durability & Dosing Paradigms Beyond Incretin Agonism
8:30 am
- Harnessing the “Bio-Blueprint” via MYO Technology™ by utilizing proprietary DNAencoded plasmid delivery to transform skeletal muscle or subcutaneous adipocytes into a sustainable bio-factory, enabling the continuous, endogenous production of therapeutic proteins that bypass the pharmacokinetic “spikes” and “troughs” of traditional biologics
- Engineering long-acting metabolic resilience by deploying the LNP-based Prometheus system to deliver genetic instructions for multi-pathway modulators (such as EX4 or modified GLP-1/GIP) that remain localized and active for over six months, providing a “one-and-done” metabolic reset that significantly improves liver and pancreatic function without systemic toxicity
- Pioneering a “Zero-Adherence” Treatment Framework by eliminating the psychological and physical hurdles of “jab fatigue” by replacing weekly or daily injections with ultra-long-acting DNA therapeutics, ensuring real-world efficacy that matches clinical trial performance by removing patient adherence from the therapeutic equation
